Background The mechanisms of skin aging have not been completely elucidated. Anecdotal data suggests that EGFR inhibition accelerates aging-like skin changes. Objective The objective of the study was to evaluate the clinical characteristics and investigate the cellular and molecular mechanisms underlying skin changes associated with the use of EFGRIs. Patients and methods Patients during prolonged treatment with EGFRIs (>3 months) were analyzed for aging-like skin changes. Baseline EGFR expression was compared in young (<25 years old) vs. old (> 65 years old) skin. In addition, the regulation of extracellular matrix, senescence-associated genes, and cell cycle status was measured in primary human keratinocytes treated with erlotinib in vitro. Results There were progressive signs of skin aging, including xerosis cutis, atrophy, rhytide formation, and/or actinic purpura in 12 patients. Keratinocytes treated with erlotinib in vitro showed a significant down-modulation of hyaluronan synthases (HAS2 and HAS3), whereas senescenceassociated genes (p21, p53, IL-6, maspin) were upregulated, along with a G1 cell cycle arrest and stronger SA β-Gal activity. There was significantly decreased baseline expression in EGFR density in aged skin, when compared to young controls. Conclusions EGFR inhibition results in molecular alterations in keratinocytes that may contribute to the observed skin aging of patients treated with respective targeted agents.
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Introduction
Epidermal growth factor (EGF) receptor (EGFR) inhibitors (EGFRIs) have proven to be remarkably successful in the targeted therapy of cancers of epithelial cell origin including colorectal, non-small-cell lung, pancreatic cancers, and squamous-cell carcinomas. Despite their clinical efficacy, treatment with these agents can lead to dermatologic adverse events (AEs) in more than 90 % of the treated patients, and result in dose modifications, impairment of quality of life, and patient non-compliance [1, 2] . An inflammatory papulopustular eruption ("acneiform rash"), primarily localized to seborrheic areas (e.g., face and trunk), is one of the characteristic AEs. Additionally, patients may develop xerosis cutis, pruritus, painful paronychia, bacterial skin colonization and/or superinfections, alopecia, and hair changes [3] [4] [5] [6] . This broad variety of AEs underscores the central physiological role that EGF and its receptor play in cutaneous homeostasis (including adnexae). In fact, recent studies have demonstrated that the loss of epidermal EGFR leads to induction of pro-inflammatory cytokines and chemokines, which recruit an inflammatory infiltrate into the skin. This is accompanied by a downregulation of antimicrobial peptide and barrier gene expression, leading to bacterial infections and progressive xerosis cutis [7] .
In our clinical practice, we have observed aging-like skin changes in patients receiving prolonged EGFRI treatment. Since this AE has not been hitherto recognized, we investigated the potential cellular and molecular mechanisms underlying its development, and report our findings.
Materials and methods

Study design
We retrospectively reviewed the medical records of cancer patients at three different institutions (Department of Dermatology, University of Duesseldorf, Duesseldorf, Germany; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Dermatology Service and Paris-Sud University, Gustave Roussy Cancer Campus, Paris, France) who had received prolonged treatment with an EGFRI (>3 months), and also developed aging-like skin changes. To validate our findings, we analyzed the regulation of established (skin-) aging markers in primary human keratinocytes treated in vitro with the EGFRI, erlotinib, using quantitative real-time PCR. Measured markers included the extracellular matrix (ECM)-associated genes hyaluronan synthase 2 (HAS2) and hyaluronan synthase 3 (HAS3). The progressive loss of dermal hyaluronan is a hallmark of skin aging. A major factor that contributes to this loss is the aging-associated downregulation of HAS2 and HAS3 [8, 9] . Moreover, we measured the expression of the senescence-associated genes p53 [10] , p21 [11] , maspin [12] , and IL-6 [13] . Next, we performed immunohistochemical and flow cytometric analyses of cell cycle status in erlotinib-treated primary human keratinocytes. To determine the relative expression of EGFR in skin (young vs. aged), we obtained biopsies of young skin (<25 years old, n = 4) and aged skin from healthy control volunteers (>65 years old, n = 8). In the latter, the UV-exposed (extrinsically aged) and non-UVexposed (intrinsically aged) areas were biopsied, and immunohistochemical analyses were conducted. The clinical data was sourced from all our centers, and the laboratory experiments were conducted at the University of Duesseldorf, Germany. The study was approved by the local ethics committee, and informed consent was obtained.
Culture of human epidermal cells
Human primary epidermal keratinocytes were isolated and cultured in keratinocyte serum-free medium (SFM, Invitrogen) at 37°C, 5 % CO 2 . Cells were treated with erlotinib (500 and 1000 nM; Roche Pharmaceuticals) or medium (vehicle control), either in the presence or absence of TNF-α (10 ng/ml; AbD Serotec) and IL-1β (5 ng/ml; R&D Systems) for 24 h, following which the cells were harvested for RNA extraction.
Total RNA isolation and RT-PCR analysis of human primary keratinocytes cells
Total RNA from cultured epidermal keratinocytes was isolated with TRIzol® Reagent (Invitrogen). cDNA synthesis was performed with SuperScript First-Strand Synthesis System (Invitrogen) according to the manufacturer's instructions. Primers were obtained from Eurofins MWG, Ebersberg, Germany (HAS2 forward 5′-GTG GAT TAT GTA CAG GTT TGT GA-3′, reverse 5′-TCC AAC CAT GGG ATC TTC TT-3′; HAS3 forward 5′-GAG ATG TCC AGA TCC TCA ACA A-3′, reverse 5′-CCC ACT AAT ACA CTG CAC AC-3′; p21 forward 5′-CTG GAG ACT CTC AGG GTC GAA-3′, reverse 5′-CCA GGA CTG CAG GCT TCC T-3′; p53 forward 5′-AAG AAA CCA CTG GAT GGA GAA-3′, reverse 5′-CAG CTC TCG GAA CAT CTC GAA-3′; IL-6 forward 5′-TCT CCA CAA GCG CCT TCG-3′, reverse 5′-CTC AGG GCT GAG ATG CCG-3′; Maspin forward 5′-CAG ACA CGG TCG CCT CCA CA-3′, reverse 5′-TTG CAG GGC ATC CAT TGC GG-3′). Gene-specific PCR products were measured by means of an ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA). Target gene expression was normalized to the expression of 18S rRNA.
SA β-gal enzyme activity Cellular senescence was examined by measuring senescenceassociated beta-galactosidase (SA β-Gal) activity (BioVision, Milpitas, CA). Human primary epidermal keratinocytes were grown for 24 h in 6-well plates either with erlotinib (1000 nM; Roche Pharmaceuticals) or medium (vehicle control). The culture media was then decanted, and the cells were stained for SA β-Gal activity as directed by the supplier (BioVision). Histologic images were acquired with a Zeiss microscope (Axiovert 200 M) (Zeiss, Jena, Germany) using Axiovision 4.7 software (Zeiss).
Flow cytometric cell cycle analysis
Cell cycle analysis of keratinocytes was performed via flow cytometry. In short, the cells were harvested by trypsinization and washed two times with PBS. Subsequently, the nuclei were isolated via incubation in a hypotonic buffer containing propidium iodide (0.1% sodium citrate, 0.1% Triton X-100, 50 µg/μL propidium iodide). The stained DNA content of the nuclei was analyzed in a FACS-Calibur (BD Bioscience), and the measured peaks corresponding to certain cell cycle phases (G1: 2n; G2 or M: 4n; S-Phase in between) were quantified with the CellQuest software (BD Bioscience).
Immunofluorescence
Cryosections from young (age < 25 years) and aged (age > 65 years) human skin were routinely fixed and stained with an antibody directed against human EGFR (mouse monoclonal; DAKO, Hamburg, Germany) or IgG1 isotype control antibody (R&D Systems, Minneapolis, MN). Primary antibody binding was detected using the secondary antibody anti-mouse IgG Alexa Fluor 555 (Life Technologies, Carlsbad, CA). Sections were fixed with Fluoromount G and immunoreactions were detected by use of the microscope Axiovert 200 M (Zeiss, Jena, Germany) using Axiovision 4.7 software (Zeiss). For quantification of EGFR staining, computer-assisted image analyses were performed using NIS Elements AR software (NIKON, Duesseldorf, Germany).
Statistical analysis
Data are represented as means ± SEM, and were evaluated with a two-tailed, unpaired Student's t test with 95% confidence intervals. The p value of ≤0.05 was taken to be statistically significant, and the values are represented with asterisks in the figures (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).
Results
Aging skin phenotype in long-term EGFRI-treated patients
We identified a total of 12 patients with a mean age of 65.4 years (range, 62-74 years), who had all developed characteristic signs of skin aging during long-term therapy with EGFRIs. As signs of (skin-) aging in tumor patients are often associated with significant weight loss or general wasting, concomitant anti-tumor therapies, or systemic steroids, we did not include patients in our analyses that fulfilled any of these criteria. Four drugs (erlotinib, gefitinib, dacomitinib, cetuximab) were represented in our patient group; however, dermatologic AEs were associated with all drugs, suggestive of a "class effect." Patients presented with progressive generalized xerosis cutis, rhytides (wrinkles), skin atrophy, skin fragility (purpura, erosions, and lacerations upon minimal trauma), atrophy of the subcutaneous tissue, and/or actinic purpura favoring UV-exposed areas (Fig. 1a-e) . All patients acknowledged that their skin-appearance was ageappropriate prior to EGFRI treatment, and that the changes developed within months after initiation of the EGFRI.
Comparative analysis of EGFR density in aged vs. young skin
Immunofluorescence analyses of skin sections revealed a significant decline in EGFR density in aged skin, as compared to young skin. This was true for samples obtained from the UVexposed (p ≤ 0.01) as well as non-UV-exposed (p ≤ 0.001) areas. In the latter, however, the EGFR density in both the areas was comparable (Fig. 2a-d) .
Effect of erlotinib on primary human keratinocytes in vitro
Expression of hyaluronan synthase genes
The expression of the genes, HAS2 and HAS3, was significantly impaired in a dose-dependent manner following incubation with erlotinib for 24 h, both in the presence and absence of the pro-inflammatory cytokines TNF-α and IL-1β (Fig. 3a,  b) .
Expression of senescence-associated genes
There was a statistically significant increase in the expression of senescence-associated genes p21, p53, IL-6, and maspin, as compared to controls (Fig. 3c-f) . Moreover, primary human keratinocytes treated with erlotinib (1000 nM) showed a stronger SA β-Gal activity as compared to medium-treated controls (Fig. 3g, h ).
Effect on cell cycle
In order to further investigate the senescence-inducing effect of erlotinib, we determined the cell cycle phase distribution in primary human keratinocytes after treatment with erlotinib for up to 48 h. Interestingly, and in concordance with its senescence-inducing effect (Fig. 3c-h ), treatment with erlotinib leads to strong time-dependent increase in cells in the G 1 -phase (Fig. 3j) . On the other hand, populations of cells residing in the S-and G 2 -phase were markedly decreased (Fig. 3k,  l) . This indicates the formation of a G 1 -arrest induced by erlotinib, finally leading to cellular senescence.
Discussion
The present study is the first to describe the clinical characteristics and molecular basis for an "aging-skin" phenotype occurring in patients receiving long-term EGFRI treatment. The most frequent manifestations of this phenotype include xerosis cutis and rhytides, besides atrophy of the skin and subcutaneous tissue, skin fragility, and/or actinic purpura (Fig. 1a-e) . Our in vitro studies have demonstrated the significant down-modulation of HAS genes, induction of senescence-associated genes, and a cell cycle arrest in the G 1 phase, all of which further corroborate our clinical observations. Moreover, there is now accumulating evidence that skin aging may manifest as a chronic cutaneous insufficiency/ fragility syndrome, referred to as dermatoporosis. Clinical characteristics of this advanced stage of skin aging include: (a) morphological markers of fragility, such as purpura (Fig. 1d) or skin atrophy (Fig. 1c) and (b) a functional expression of skin fragility, including skin lacerations resulting from minor trauma (Fig. 1e) [14] .
In general, skin aging is a consequence of genetic programming (intrinsic aging) and/or exposure to environmental factors (extrinsic aging; e.g., UV rays, drugs). Yet, even under extreme conditions, the development of an advanced "skinaging" phenotype similar to that seen in our patients would require years to develop. It is likely that chronic UV exposure predisposes to EGFRI-induced skin aging, as the skin alterations in our patients were observed almost exclusively in UVexposed areas (face, neck, arms), and it has been shown that the EGFRI-induced rash also can be aggravated or even provoked by UV exposure [15] . On the other hand, it is rather unlikely that acute UV exposure could have played a major role, as our patients were advised intensive sun-protection measures at the initiation of EGFRI therapy. Furthermore, none of our patients had received extensive doses of systemic or topical glucocorticosteroids, ruling out this potential cause of skin atrophy. Taken together, our clinical observations and in particular, the short time-period for the development of the AEs presented here, suggest that impaired EGFR signaling may promote human (skin) aging. This hypothesis is supported by the fact that intrinsically aged skin, and the skin of patients treated with an EGFRI, share common histopathologic characteristics such as atrophic epidermis, with a thin, compact stratum corneum [16, 17] .
An age-related reduction in EGF/EGFR levels has been observed in a number of settings. Recent studies in Caenothabditis elegans longevity models demonstrate that Fig. 3 a-l Erlotinib impairs the expression of hyaluronan synthase genes, induces senescence-associated genes and SA β-galactosidase activation as well as a time-dependent G 1 cell cycle arrest in primary human keratinocytes in vitro. a-f mRNA expression of a HAS2, b HAS3, c p21, d p53, e IL-6, and f maspin in primary human keratinocytes treated with erlotinib (0 nM, 500 nM, 1000 nM) for 24 h, in case of a and b in the presence or absence of the pro-inflammatory cytokines TNF-α (10 ng/ml) and IL1β (5 ng/ml). g-h Cells were incubated overnight with g medium (vehicle control) or h erlotinib (1000 nM), fixed and incubated with X-gal, and analyzed by microscopy. j-l For flow cytometric cell cycle analysis, cells were treated with erlotinib (1000 nM) for up to 48 h. Displayed are percentages of cells in the j G 1 -, k S-, and l G 2 -phase. Data shown represent the mean ± SEM of three independent experiments (Student's t test; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). RU relative units reducing the activity of EGF signaling is associated with system-wide evidence of aging-related changes [18] [19] [20] . Similar effects were noted by Shurin and coworkers in humans. Of the 30 serum biomarkers tested, they identified EGF and EGFR as the two candidates with the most significant down-modulation with age, in contrast to the interferoninduced chemokines, CXCL9 (MIG), CXCL10 (IP-10), and CCL11 (eotaxin), and IL-6 which were all increased by aging [21] . While in skin, Green et al. demonstrated a downregulation of EGFR on basal epidermal keratinocytes and dermal fibroblasts in the dorsal skin of young (neonatal, day 1) vs. old (days 23 or 51) rats [22] . In addition, Shiraha et al. demonstrated decreased levels of EGFR on old vs. young human dermal fibroblasts [23] . This argues well that EGFR decline may be associated with impaired regenerative capacities of aging skin. In this context, and to the best of our knowledge, we here for the first time have demonstrated a decline in (epidermal) EGFR levels in "young" (<25 years) vs. "aged" (UV-exposed: "old extrinsic"; non-UV-exposed: "old intrinsic) human skin (>65 years) (Fig. 2) .
But what is known about a link between reduced EGFR and skin aging? In general, two major hypotheses for the mechanisms of intrinsic skin aging have been proposed: (a) the oxidative stress theory of skin aging suggests that aging is heavily influenced by external stressors which influence the genetic program through the modulation of redox-sensitive genes, and, (b) the cellular senescence theory that invokes a combination of factors including (i) decreased proliferation of skin cells, (ii) decreased matrix synthesis, and (iii) increased expression of matrix-degrading enzymes in skin aging [24] . In this hypothesis, few senescent cells may exert significant deleterious effects on the tissue microenvironment and promote aging and/or tumor progression ("Senescent cells are good citizens but bad neighbours!") [25, 26] .
The EGFR has been shown to play a central role for oxidative stress-driven skin aging. Under physiological conditions, the EGFR is activated by the binding of specific ligands such as EGF or transforming growth factor-α (TGF-α) [27] . Yet, exogenous stimuli, such as UV-and gamma-irradiation, H 2 O 2 , or polycyclic aromatic hydrocarbons, can also activate the EGFR via the generation of reactive oxygen species (ROS) in a ligand-independent manner [28, 29] . These effects become evident when the generation of ROS exceeds cellular scavenger capacities (stress tolerance), resulting in oxidative stress. Stress-induced activation of EGFR signaling leads to the activation of the transcription factor activator protein (AP-1), and finally to an induction of matrix metallo-proteinases, eventually resulting in extrinsic skin aging [30] . In this context, pharmacological inhibition of EGFR and/or EGFR-dependent signaling pathways have been proposed as a strategy for the prevention of photoaging [31] [32] [33] . However, it has also been shown that pharmacological EGFR inhibition results in an increase of UVB-induced H 2 O 2 generation and hence, increased oxidative stress in primary human keratinocytes [34] . Furthermore, hepatocytes obtained from old rats (24-26 months) were more sensitive to H 2 O 2 as compared to those obtained from young rats (4-6 months). This effect could be mimicked in young hepatocytes by pharmacological inhibition of the EGFR downstream kinases ERK and Akt [35] . Hence, it can be proposed that the activation status of the EGFR may influence skin aging in multifarious ways and that other variables that determine pro-and anti-aging effects still need to be identified (e.g., acute UV-induced EGFR activation vs. chronic pharmacological EGFR inhibition).
With regard to the cellular senescence theory of skin aging, decreased EGFR expression in aging skin has been associated with decreased proliferative capacities that may clinically correlate with impaired wound healing in the elderly [23] . We have recently shown that pharmacologically or genetically impaired EGFR signaling induces the expression of proinflammatory cytokines and chemokines, such as IL-6, IL- The deprivation of an essential growth factor results in impairment of regenerative capacities and impaired ECM synthesis, 2 EGFR inhibition causes premature cellular senescence and induces a SASP that affects neighboring cells, and 3 EGFR inhibition reduces cellular stress tolerance and promotes a UV-induced cell cycle arrest 1α, IL-1β, CCL2, CXCL1, and CXCL2, that define a senescence-associated secretory phenotype (SASP) [7, 36] . Furthermore, we have demonstrated that the EGFR is critically involved in TGF-β1-induced hyaluronan (HA) synthesis and HA signaling. Strikingly, pharmacological EGFR inhibition blocked the paracrine effect of UBB-plus estrogen (E2)-treated epidermal keratinocytes on dermal fibroblasts and suppressed the expression of HAS3 and versican (V2) and hence ECM synthesis [37] . Our current data are consistent with these findings and demonstrate that the EGFRI, erlotinib, significantly and dose-dependently impairs the expression of HAS2 and HAS3 in primary human keratinocytes in vitro (Fig. 3a, b) . Furthermore, pharmacological inhibition of the EGFR and its downstream kinase BRAF have been shown to induce premature senescence in a variety of cell types, including non-small cell lung cancer or melanoma cells [38, 39] . A recent study by Schad and coworkers outlined similarities in dermatologic AEs in patients treated with MEK inhibitors, and patients treated with EGFRIs. In this context, the authors proposed that long-term inhibition of the EGFR downstream kinase MEK may result in a phenotype that resembles senescence-driven skin aging [40] . Again, these findings are in line with our data that demonstrate that erlotinib significantly and dose-dependently induces the expression of senescence-associated genes (p21, p53, IL-6, maspin) ( Fig. 3c-f) , as well as SA β-gal activity (Fig. 3g, h) .
Finally, we demonstrate that erlotinib is capable of inducing G 1 cell cycle arrest of primary human keratinocytes (Fig. 3j-l) . This is consistent with the findings of El-Abaseri et al. that show that activation of EGFR, in this case using UV irradiation, leads to cell proliferation, but in absence of the receptor (EGFR −/− mouse skin) cell cycle arrest and apoptosis occurs with an increase in p21 and p53 levels. Thus, absence or reduction of EGFR signaling leads to an increase in senescence associated with cell cycle arrest [41] . Hence, there is accumulating evidence demonstrating that EGFR inhibition promotes processes that are critical to skin aging. These proaging effects may affect both the oxidative stress and senescence-driven aging, and are likely to exert multiple alterations in signaling pathways.
To conclude, targeted inhibition of signaling pathways involved in the survival and growth of tumor cells has extended the therapeutic armamentarium for the management of cancer. Paradoxically, the associated AEs of these drugs have also been valuable and given medical research new insights into the physiological functions of these pathways. Inhibition of the EGFR has uncovered a critical role for EGF and its receptor in the homeostasis of normal human skin and skin aging. The changes that lead to premature skin aging are summarized in a hypothetical model (Fig. 4) . With this concept in hand, future studies on the mechanisms of aging can be focused on confirming the relationships proposed and should also focus to discriminate acute effects, such as the activation of EGFR signaling by UV, from chronic effects such as a long-term pharmacologic inhibition of the EGFR and its downstream kinases by targeted cancer agents.
